AbbVie Stock Rises 12% in a Month: Should Investors Buy, Sell, or Hold ABBV Now?
AbbVie Stock Rises 12% in a Month: Should Investors Buy, Sell, or Hold ABBV Now?
AbbVie has returned to investors’ watchlists after ABBV stock climbed sharply over the past month. The move has raised a key question: should investors buy, sell, or hold AbbVie shares after this strong rally?
Why ABBV Stock Is Gaining Attention
AbbVie’s recent stock strength is linked to renewed confidence in its drug portfolio, strong earnings results, and improving investor sentiment toward large pharmaceutical companies. The company reported better-than-expected first-quarter 2026 results, with revenue of about $15 billion and adjusted earnings of $2.65 per share, beating Wall Street expectations. AbbVie also raised its 2026 adjusted EPS guidance to a range of $14.08 to $14.28.
The biggest driver remains AbbVie’s immunology business. Skyrizi and Rinvoq continue to offset the decline of Humira, which has faced biosimilar competition. In Q1 2026, Skyrizi sales rose around 31% year over year, while Rinvoq sales increased about 23%.
Key Growth Drivers Behind AbbVie
Skyrizi and Rinvoq Are Leading the Recovery
AbbVie’s future growth depends heavily on Skyrizi and Rinvoq. These two medicines have become the company’s most important immunology assets. As Humira sales continue to fall, investors are watching whether these newer treatments can support long-term revenue growth.
So far, the answer looks positive. Skyrizi has performed strongly across autoimmune diseases, while Rinvoq remains a major contributor in inflammatory conditions. Their combined growth gives AbbVie a stronger base than many investors expected after Humira lost exclusivity.
Neuroscience and Aesthetics Add Balance
AbbVie is not only an immunology company. Its neuroscience portfolio, including Botox Therapeutic and Vraylar, adds another growth stream. The aesthetics business, which includes Botox Cosmetic and Juvederm, gives AbbVie exposure to consumer healthcare trends as well.
This mix helps reduce dependence on one product. That matters because pharmaceutical companies face patent risks, pricing pressure, and clinical trial uncertainty.
Risks Investors Should Watch
Despite the strong rally, ABBV stock is not risk-free. Humira sales are still declining due to biosimilar competition. Competition is also rising in immunology, especially from rival drugs in similar treatment areas. Some analysts remain cautious because investor sentiment can shift quickly if Skyrizi or Rinvoq growth slows.
Another risk is valuation. After a 12% monthly rise, some near-term upside may already be priced in. Investors buying after a rally should be careful not to chase momentum without reviewing earnings growth, dividend safety, and pipeline progress.
Should Investors Buy, Sell, or Hold ABBV?
For long-term investors, holding ABBV stock appears to be the most balanced approach. AbbVie has strong cash flow, a broad medicine portfolio, and improving growth from Skyrizi and Rinvoq. The company also offers a dividend, which remains attractive for income-focused investors.
Aggressive investors may still consider buying on pullbacks, especially if they believe AbbVie can keep growing beyond the Humira decline. However, after a sharp monthly gain, waiting for a better entry point may be wise.
Selling may only make sense for investors who already have large gains, need to reduce healthcare exposure, or worry that competition will pressure AbbVie’s growth outlook.
Final Takeaway
AbbVie’s recent 12% rise shows that investors are regaining confidence in the company. Strong Q1 results, higher guidance, and solid demand for Skyrizi and Rinvoq support the bullish case. Still, risks from competition, pricing pressure, and Humira’s decline remain important.
Overall, ABBV looks more like a hold than an urgent buy after its latest rally. Long-term investors may stay invested, while new buyers may want to wait for a more attractive price.
Disclaimer: This article is for informational purposes only and is not financial advice. Investors should do their own research or speak with a licensed financial adviser before making investment decisions.
#ABBV #AbbVieStock #HealthcareStocks #StockMarketNews #SlimScan #GrowthStocks #CANSLIM